Data / Form D filings / Regenacy Pharmaceuticals, Inc.
Regenacy Pharmaceuticals, Inc.: Form D filings
Regenacy Pharmaceuticals, Inc., a pharmaceuticals company in Waltham, MA, filed 2 Form D notices with the SEC between 2020 and 2022. The latest, on February 10, 2022, reports $7.8 million sold of a $10 million offering to 9 investors.
Find out what Regenacy Pharmaceuticals, Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 303 Wyman Street, Suite 300, Waltham, MA, 02451
- Phone
- (617) 415-5030
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1807611
The full lists. Form D filings in Massachusetts: 1,533 rows, $76.65, or the new rows each week for $19 a month. Form D filings in Pharmaceuticals: 346 rows, $17.30, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Feb 10, 2022 | New notice | $9,999,999 | $7,808,997 | $2,191,002 | 9 | Jan 27, 2022 | sec.gov |
| Apr 8, 2020 | New notice | $40,707,421 | $20,857,418 | $19,850,003 | 19 | Mar 24, 2020 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Daguang L. Wang | Director | |
| William L. Chin | Director | |
| Simon Jones | Executive Officer, Director | |
| Shixiang L. Yan | Director | |
| Michael L. Huang | Director | |
| Marc Cohen | Executive Officer, Director | |
| John Rocha | Executive Officer |
Other pharmaceuticals companies in Massachusetts that filed recently
- BridgeHealth Pharmaceuticals, Inc. $3.5 million · Nov 5, 2026
- Land Therapeutics Inc. $17.5 million · Oct 21, 2026
- Crosslink Therapeutics Inc. $5.5 million · Oct 20, 2026
- Sentonix, Inc. $12.7 million · Aug 20, 2026
Every Form D from the week of Feb 7, 2022 · All recent filings in Massachusetts · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what Regenacy Pharmaceuticals, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.